(Q45143982)

10 December 2017

title

HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine (English)

1 reference

10 December 2017

0 references

1 reference

1 reference

4

1 reference

10 December 2017

Erin K Quirk

1

1 reference

10 December 2017

Robin Mogg

2

1 reference

10 December 2017

Deborah D Brown

3

1 reference

10 December 2017

Devan V Mehrotra

5

1 reference

10 December 2017

Mark J DiNubile

6

1 reference

10 December 2017

Michael N Robertson

7

1 reference

10 December 2017

language of work or name

English

0 references

publication date

1 December 2008

1 reference

Clinical Infectious Diseases

10 December 2017

published in

1 reference

10 December 2017

volume

47

1 reference

10 December 2017

issue

12

1 reference

10 December 2017

page(s)

1593-1599

1 reference

HIV epidemiology update and transmission factors: risks and risk contexts--16th International AIDS Conference epidemiology plenary.

10 December 2017

cites work

1 reference

HIV vaccines: new frontiers in vaccine development

21 January 2018

1 reference

An HIV vaccine--evolving concepts

21 January 2018

1 reference

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

21 January 2018

1 reference

The challenge of HIV-1 subtype diversity

21 January 2018

1 reference

Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection.

21 January 2018

1 reference

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

21 January 2018

1 reference

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

21 January 2018

1 reference

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

21 January 2018

1 reference

Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients

21 January 2018

1 reference

Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial

21 January 2018

1 reference

Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States

21 January 2018

1 reference

21 January 2018

1 reference

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses

21 January 2018

1 reference

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

21 January 2018

1 reference

Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes

21 January 2018

1 reference

The hunt for an HIV vaccine: time to rethink recent failures

21 January 2018

1 reference

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/593313

1 reference

10 December 2017

1 reference